ProtAb Company

ProtAb develops therapeutic agents that modulate cytokine regulation, tipping the balance toward anti-inflammatory signaling pathways in the treatment of autoimmune and inflammatory diseases. Its first product, Prozumab, is a monoclonal antibody with a novel mechanism of action. It is currently in late-stage preclinical development for the treatment of inflammatory bowel disease or IBD, ulcerative colitis or UC, and rheumatoid arthritis or RA. It operates as a subsidiary of Hadasit Bio-Holdings. HBL is a publicly traded subsidiary of Hadasit, the technology transfer company of the Hadassah University Hospital in Jerusalem in Israel.
Technology: Others
Industry: Biotechnology, Health Care, Science and Engineering
Headquarters: Jerusalem, Yerushalayim, Israel
Founded Date: 2005-01-01
Employees Number: 1-10
Funding Status: Early Stage Venture
Investors Number: 1
Estimated Revenue: Less than $1M
Last Funding Type: Venture - Series Unknown

Visit Website
Register and Claim Ownership